The DOI matches its Crossref record; 428 of the 428 references it cites were found in a registry or an index.
Genetics and biology of pancreatic ductal adenocarcinoma
Open accessAbstract
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in the United States with a median survival of <6 mo and a dismal 5-yr survival rate of 3%–5%. The cancer’s lethal nature stems from its propensity to rapidly disseminate to the lymphatic system and distant organs. This aggressive biology and resistance to conventional and targeted therapeutic agents leads to a typical clinical presentation of incurable disease at the time of diagnosis. The well-defined serial histopathologic picture and accompanying molecular profiles of PDAC and its precursor lesions have provided the framework for emerging basic and translational research. Recent advances include insights into the cancer’s cellular origins, high-resolution genomic profiles pointing to potential new therapeutic targets, and refined mouse models reflecting both the genetics and histopathologic evolution of human PDAC. This confluence of developments offers the opportunity for accelerated discovery and the future promise of improved treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–428 of 428
Wagner, M., Lopez, M. E., Cahn, M., & Korc, M. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70594-3 · Cited by 66
Polymorphisms of SPINK1 N34S and CFTR in Patients with Sporadic and Familial Pancreatic Cancer
Matsubayashi, H., & Fukushima, N. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.6.530 · Cited by 66
Peng, B., Fleming, J. B., Breslin, T. M., Grau, A. M., Fojioka, S., Abbruzzese, J. L., Evans, D. B., Ayers, D., Wathen, K., Wu, T., et al. (2002) · PubMed · Cited by 66
McWilliams, R. R., Highsmith, W. E., Rabe, K. G., de Andrade, M., Tordsen, L. A., Holtegaard, L. M., & Petersen, G. M. (2005) · Gut · doi:10.1136/gut.2005.074534 · Cited by 64
Sclabas, G. M., Fujioka, S., Schmidt, C., Evans, D. B., & Chiao, P. J. (2003) · International Journal of Gastrointestinal Cancer · doi:10.1385/ijgc:33:1:15 · Cited by 63
Dominant negative MEKK1 inhibits survival of pancreatic cancer cells
Hirano, T., Shino, Y., Saito, T., Komoda, F., Okutomi, Y., Takeda, A., Ishihara, T., Yamaguchi, T., Saisho, H., & Shirasawa, H. (2002) · Oncogene · doi:10.1038/sj.onc.1205643 · Cited by 62
Scoggins, C. R., Meszoely, I. M., Wada, M., Means, A. L., Yang, L., & Leach, S. D. (2000) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2000.279.4.g827 · Cited by 61
Pao, W. J., Klimstra, D. S., Fisher, G. H., & VARMUS, H. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1133333100 · Cited by 59
Armengol, G., Knuutila, S., Lluı́s, F., Capellá, G., Miró, R., & Caballín, M. R. (2000) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(99)00118-1 · Cited by 58
LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer
Li, J., Zhang, Z., Zunyan Dai, Y., Plass, C., Morris, Q., Wang, Y., Wiest, J. S., Anderson, M. W., & You, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206192 · Cited by 58
Signal Transduction: IMPlications for Ras-Dependent ERK Signaling
Ory, S., & Morrison, D. K. (2004) · Current Biology · doi:10.1016/j.cub.2004.03.023 · Cited by 57
Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer
Xing, H., Cordon‐Cardo, C., Deng, X., Tong, W. P., Campodonico, L., FUKS, Z. Y., & Kolesnick, R. N. (2003) · Nature Medicine · doi:10.1038/nm927 · Cited by 56
Zhang, Z., Jiang, G., Yang, F., & Wang, J. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.11.3297 · Cited by 54
Sirivatanauksorn, V., Sirivatanauksorn, Y., Gorman, P. A., Davidson, J. M., Sheer, D., Moore, P. S., Scarpa, A., Edwards, P. A., & Lemoine, N. R. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(200002)9999:9999<::aid-ijc1049>3.3.co;2-3 · Cited by 54
Ostrander, J. H., Hawke, N. A., Kashatus, D. F., & Baldwin, A. S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3898 · Cited by 52
A Metabolic Hypothesis of Cell Growth and Death in Pancreatic Cancer
Boros, L. G., Lee, W. P., & Go, V. L. W. (2002) · Pancreas · doi:10.1097/00006676-200201000-00004 · Cited by 51
Yoshida, T., & Hanahan, D. (1994) · PubMed · Cited by 45
Kornmann, M., Ishiwata, T., Matsuda, K., Lopez, M. E., Fukahi, K., Asano, G., Beger, H. G., & Korc, M. (2002) · Gastroenterology · doi:10.1053/gast.2002.34174 · Cited by 45
Kuniyasu, H., Abbruzzese, J. L., Cleary, K. R., & Fidler, I. J. (2001) · International Journal of Oncology · doi:10.3892/ijo.19.4.681 · Cited by 44
Familial Pancreatic Cancer: Where Are We in 2003?
Petersen, G. M., & Hruban, R. H. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.3.180 · Cited by 44
CA1A2X-competitive inhibitors of farnesyltransferase as anti-cancer agents
Omer, C. A., & Kohl, N. E. (1997) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)01129-2 · Cited by 35
McCormick, F. P. (1998) · Current Biology · doi:10.1016/s0960-9822(98)70431-2 · Cited by 32
CA1A2X-competitive inhibitors of farnesyltransferase as anti-cancer agents
Omer, C. A., & Kohl, N. E. (1997) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)90677-5 · Cited by 27
Hotz, H. G., Hines, O. J., Hotz, B., et al. (2003) · Journal of Gastrointestinal Surgery · doi:10.1016/s1091-255x(02)00157-9 · Cited by 26
Glasner, S. D., Memoli, V. A., & Longnecker, D. S. (1992) · PubMed · Cited by 21
Kleeff, J. H., Kothari, N. H., Frieß, H., Fan, H., & Korc, M. (2003) · Pancreas · doi:10.1097/00006676-200401000-00004 · Cited by 18
Specific Amino Acid Profile in Culture Media Conditioned by Human Pancreatic Cancer Cell Lines
Wang, F., & Permert, J. (2002) · Pancreatology · doi:10.1159/000065088 · Cited by 6
(2000) · doi:10.1002/(sici)1098-2264(200004)27:4
Cited by
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Kamerkar, S., LeBleu, V. S., Sugimoto, H., Yang, S., Ruivo, C. F., Melo, S. A., Lee, J. J., & Kalluri, R. (2017) · Nature · doi:10.1038/nature22341 · Cited by 2,639
EMT and Dissemination Precede Pancreatic Tumor Formation
Rhim, A. D., Mirek, E. T., Aiello, N. M., Maitra, A., Bailey, J. M., McAllister, F., Reichert, M., Beatty, G. L., Rustgi, A. K., Vonderheide, R. H., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.025 · Cited by 2,136
Self-citationOncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Self-citationKleeff, J., Korc, M., Apte, M., La Vecchia, C., Johnson, C. D., Biankin, A. V., Neale, R. E., Tempero, M., Tuveson, D. A., Hruban, R. H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.22 · Cited by 1,982
Pancreatic cancers require autophagy for tumor growth
Yang, S., Wang, X., Contino, G., Liesa, M., Sahin, E., Ying, H., Bause, A., Li, Y., Stommel, J. M., Dell'Antonio, G., et al. (2011) · Genes & Development · doi:10.1101/gad.2016111 · Cited by 1,498
Self-citation
Metadata
- Authors
- Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N., & DePinho, R. A.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2006-05-15
- Volume
- 20
- Issue
- 10
- Pages
- 1218-1249
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2099023480
- Cited by
- 1,577
- References
- 428
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.